Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1967 Dec;46(12):1979–1985. doi: 10.1172/JCI105687

Studies of the Metabolism and Distribution of Fibrinogen in Patients with Hemophilia A*

Y Takeda 1,‡, Alan Y Chen 1
PMCID: PMC292950  PMID: 6074002

Abstract

Using autologous 131I-fibrinogen, we made studies of the metabolism and distribution of fibrinogen in 10 patients with hemophilia A. In two patients simultaneous studies of autologous 131I-fibrinogen and homologous 125I-fibrinogen prepared from healthy donors' plasma were carried out. The average value for the plasma volume was 42.1 ± 8.8 ml/kg; for the plasma fibrinogen concentration, 349 ± 90 mg/100 ml; for the intravascular fibrinogen, 144 ± 32 mg/kg; for the interstitial fibrinogen, 30 ± 11 mg/kg; for the slower half-life of 131I-fibrinogen, 2.34 ± 0.17 days; for the transcapillary transfer rate of fibrinogen, 109 ± 37 mg/kg per day; and for the catabolic and synthetic rates of fibrinogen, 51.7 ± 13.1 mg/kg per day. Comparison of these results with those of the previous study in healthy male subjects showed that in patients with hemophilia A the catabolic and synthetic rates of fibrinogen are markedly increased, whereas the plasma fibrinogen concentration, intravascular and interstitial fibrinogen, and the transcapillary transfer rate of fibrinogen are not significantly different. The simultaneous studies of autologous 131I-fibrinogen and normal homologous 125I-fibrinogen in two subjects revealed that the two preparations behaved very similarly. Based on these findings, we concluded that our present findings are not due to the qualitative difference between the hemophilia A and normal fibrinogens, but that they are due to the difference in the host condition with respect to the fibrinogen metabolism, which is either an increased rate of direct breakdown of fibrinogen or an increased rate of fibrinogen breakdown after fibrin formation, or both.

Full text

PDF
1979

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABILDGAARD C. F., CORNET J. A., FORT E., SCHULMAN I. THE IN VIVO LONGEVITY OF ANTIHAEMOPHILIC FACTOR (FACTOR VIII). Br J Haematol. 1964 Apr;10:225–237. doi: 10.1111/j.1365-2141.1964.tb00697.x. [DOI] [PubMed] [Google Scholar]
  2. ADELSON E., RHEINGOLD J. J., PARKER O., BUENAVENTURA A., CROSBY W. H. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood. 1961 Mar;17:267–281. [PubMed] [Google Scholar]
  3. BIGGS R., DENSON K. W. THE FATE OF PROTHROMBIN AND FACTORS VIII, IX AND X TRANSFUSED TO PATIENTS DEFICIENT IN THESE FACTORS. Br J Haematol. 1963 Oct;9:532–547. doi: 10.1111/j.1365-2141.1963.tb05478.x. [DOI] [PubMed] [Google Scholar]
  4. Blombäck B., Carlson L. A., Franzén S., Zetterqvist E. Turnover of 131-I-labelled fibrinogen in man. Studies in normal subjects, in congenital coagulation factor deficiency states, in liver cirrhosis, in polycythemia vera and in epidermolysis bullosa. Acta Med Scand. 1966 May;179(5):557–574. doi: 10.1111/j.0954-6820.1966.tb07973.x. [DOI] [PubMed] [Google Scholar]
  5. CHRISTENSEN L. K. The turnover of plasma fibrinogen. Acta Med Scand. 1958 Nov 27;162(5):407–414. doi: 10.1111/j.0954-6820.1958.tb01787.x. [DOI] [PubMed] [Google Scholar]
  6. Cooksey M. W., Perry C. B., Raper A. B. Epsilon-aminocaproic acid therapy for dental extractions in haemophiliacs. Br Med J. 1966 Dec 31;2(5530):1633–1634. doi: 10.1136/bmj.2.5530.1633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. HAMMOND J. D., VEREL D. Observations on the distribution and biological half-life of human fibrinogen. Br J Haematol. 1959 Oct;5:431–438. doi: 10.1111/j.1365-2141.1959.tb04053.x. [DOI] [PubMed] [Google Scholar]
  8. Hart H. C. The biological half-life of I-131 fibrinogen. Thromb Diath Haemorrh Suppl. 1965;17:121–131. [PubMed] [Google Scholar]
  9. RAUSEN A. R., CRUCHAUD A., McMILLAN C. W., GITLIN D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood. 1961 Dec;18:710–716. [PubMed] [Google Scholar]
  10. REEVE E. B., BAILEY H. R. Mathematical models describing the distribution of I-131-albumin in man. J Lab Clin Med. 1962 Dec;60:923–943. [PubMed] [Google Scholar]
  11. TAKEDA Y., REEVE E. B. Distribution and excretion of I-131-iodide in men on pharmacologic doses of iodides. J Lab Clin Med. 1962 Dec;60:944–953. [PubMed] [Google Scholar]
  12. TAKEDA Y., REEVE E. B. Studies of the metabolism and distribution of albumin with autologous I131-albumin in healthy men. J Lab Clin Med. 1963 Feb;61:183–202. [PubMed] [Google Scholar]
  13. Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen. J Clin Invest. 1966 Jan;45(1):103–111. doi: 10.1172/JCI105314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. VON KAULLA K. N., SCHULTZ R. L. Methods for the evaluation of human fibrinolysis; studies with two combined technics. Am J Clin Pathol. 1958 Feb;29(2):104–112. doi: 10.1093/ajcp/29.2.104. [DOI] [PubMed] [Google Scholar]
  15. VON KAULLA K. N., SWAN H. Clotting deviations in man associated with open-heart surgery during hypothermia. J Thorac Surg. 1958 Dec;36(6):857–868. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES